Forest Laboratories, Inc.
909 Third Avenue
New York
New York
10022-4731
United States
Tel: 212-421-7850
Fax: 212-750-9152
Website: http://www.frx.com/
About Forest Laboratories, Inc.
Explore your potential. Discover the rewards.
At Forest Laboratories, we believe in the power of potential. As one of the fastest growing pharmaceutical companies, we are committed to developing a talented, diverse workforce where individuals can learn, achieve and grow.
Highly skilled scientific teams within our Forest Research Institute enable us to license compounds at virtually any stage—from preclinical development to products that are ready for FDA review—and then complete the development and regulatory work to successfully bring these new products to market. Our products, including Lexapro®, Namenda® and Benicar®, help treat a range of conditions such as depression, anxiety, Alzheimer’s disease and hypertension.
In addition to further developing our established therapeutic franchises (central nervous system, cardiovascular and respiratory), we are expanding the scope of our pipeline to address a wider range of health concerns that affect people every day, such as inflammation and pain. This growth is creating significant new career opportunities, and we invite energetic, skilled professionals to join Forest and contribute to our future success.
Employees are the engine of our rapid growth, and in return we offer the incentives and benefits for a healthy work/life balance.
For career opportunities on Long Island, New Jersey and NYC please visit: www.frx.com
Last Updated: 06-01-2006
404 articles with Forest Laboratories, Inc.
-
Not everyone is so confident that Aduhelm will transform the Alzheimer’s drug development landscape.
-
Allergan's Forest Labs Pays $750 Million to Settle Class Action Suit Over Alzheimer's Drug
10/28/2019
The plaintiffs in the case alleged that Forest intentionally attempted to delay and impair generic competition of its immediate-release formulation of Namenda. -
Generation Bio Appoints Jeff Jonas M.D. to its Board of Directors
6/7/2018
Generation Bio today announced the appointment of Jeff Jonas, M.D., chief executive officer of Sage Therapeutics, to its Board of Directors.
-
Hildred Capital Partners to Invest in Crown Laboratories
10/31/2017
Hildred Capital Partners announced that Hildred has entered into an agreement under which it will assume a major stake in Crown Laboratories.
-
Fortress Biotech Forms Cellvation, Taps Forest, Life Technologies Alum as Interim CEO
11/7/2016
-
Canadian Ropack Snaps Up NY Site After Forest Decamps to New Jersey
6/26/2015
-
Actavis Takes Axe To Forest Laboratories, Inc. Again; Cuts 100 Jobs In New York
10/24/2014
-
Forest Laboratories, Inc. Lays Off 200; Regional Sales Office Will Remain
7/10/2014
-
Actavis Announces Final Stockholder Merger Consideration Election Results In Connection With Forest Laboratories, Inc. Acquisition
7/2/2014
-
Actavis plc Appoints New Members And Announces Changes To Board Of Directors Following Close Of Forest Laboratories, Inc. Acquisition
7/1/2014
-
Actavis Completes Forest Laboratories, Inc. Acquisition
7/1/2014
-
Actavis And Forest Laboratories, Inc. Receive U.S. FTC Clearance For Actavis' Proposed Acquisition Of Forest
7/1/2014
-
Actavis And Forest Laboratories, Inc. Announce Preliminary Stockholder Merger Consideration Election Results
6/30/2014
-
Actavis And Forest Laboratories, Inc. Announce Tentative Election Deadline Of June 27, 2014
6/24/2014
-
Forest Laboratories, Inc. To Present Cariprazine Data At The International College Of Neuropsychopharmacology World Congress
6/23/2014
-
Actavis And Forest Laboratories, Inc. Announce Appointment Of C. David Nicholson, Phd To Lead Actavis Global Brands Research And Development
6/23/2014
-
Actavis And Forest Laboratories, Inc. Shareholders Approve Proposals Related To Actavis' Planned Acquisition Of Forest
6/18/2014
-
Actavis Announces Receipt Of Requisite Consents And Expiration Of Consent Solicitations For Forest Laboratories, Inc. Senior Notes
6/13/2014
-
Forest Laboratories, Inc. Announces Intention To Continue Marketing Both NAMENDA® TABLETS And Once-Daily NAMENDA XR® Into The Fall Of 2014
6/11/2014
-
Forest Laboratories, Inc. Extends Expiration Time Of Consent Solicitations To Eliminate Existing Registration Rights Obligations On Certain Of Its Senior Notes
6/9/2014